InCarda Therapeutics

InCarda Therapeutics is a private, pre-revenue biotech company founded in 2009 and headquartered in San Francisco, with operational offices in Utah and Australia. The company is advancing a pipeline of inhaled therapies for the acute treatment of paroxysmal atrial fibrillation (AF) and atrial flutter (AFL), with programs targeting both medically supervised hospital use and patient self-administration at home. Led by a team with deep expertise in cardiology and drug development, InCarda aims to transform AFib management by offering a faster, more patient-centric alternative to current intravenous or oral systemic therapies.

Inhaled drug delivery platform for rapid, targeted administration of cardiovascular therapeutics directly to the heart via the pulmonary vasculature.

InCarda competes in the acute AFib cardioversion market against established generic IV antiarrhythmic drugs (e.g., ibutilide) and oral medications (e.g., flecainide). Its primary differentiation is the speed and targeted delivery of its inhaled platform. Longer-term, it may face competition from other novel drug modalities and non-pharmacological interventions like pulsed field ablation, which is gaining traction for longer-term rhythm control.